论文部分内容阅读
目的分析帕金森病患者采用多巴丝肼片(美多芭)联合普拉克索治疗的临床价值及安全性。方法 80例帕金森病患者,随机分为对照组和观察组,各40例。对照组患者单用美多芭治疗,观察组患者采用美多芭与普拉克索联合治疗,比较两组患者的治疗效果、不良反应发生情况、汉密尔顿抑郁量表(HAMD)评分以及生活质量评分等。结果观察组治疗总有效率为92.5%,高于对照组的75.0%,差异具有统计学意义(χ~2=4.5006,P<0.05)。观察组不良反应发生率为5.0%,低于对照组的20.0%,差异具有统计学意义(χ~2=4.1143,P<0.05)。治疗后,观察组患者HAMD评分低于对照组,差异具有统计学意义(t=12.1496,P<0.05)。治疗后,观察组患者躯体健康评分、心理健康评分、生活满意度及社会功能评分分别为(82.43±5.63)、(85.32±5.47)、(87.35±4.27)、(84.42±4.16)分,均高于对照组的(71.53±4.26)、(74.36±4.52)、(75.55±5.36)、(72.14±4.53)分,差异具有统计学意义(t=9.7645、9.7687、10.8902、12.6279,P<0.05)。结论美多芭与普拉克索联合治疗帕金森病的临床效果显著,有效改善了患者的抑郁症状,提高了患者的生活质量和临床治愈率,值得临床推广。
Objective To analyze the clinical value and safety of dopas hydrazine tablets combined with pramipexole in patients with Parkinson’s disease. Methods 80 patients with Parkinson’s disease were randomly divided into control group and observation group, 40 cases in each. The patients in the control group were treated with only metoprolol, the patients in the observation group were treated with combination of metopar and pramipexole, the treatment effect, adverse reactions, Hamilton Depression Rating Scale (HAMD) and quality of life score were compared between the two groups . Results The total effective rate of the observation group was 92.5%, which was higher than that of the control group (75.0%), the difference was statistically significant (χ ~ 2 = 4.5006, P <0.05). The incidence of adverse reactions in the observation group was 5.0%, which was lower than that in the control group (20.0%) (χ ~ 2 = 4.1143, P <0.05). After treatment, the HAMD score of observation group was lower than that of control group, the difference was statistically significant (t = 12.1496, P <0.05). After treatment, the physical health scores, mental health scores, life satisfaction and social function scores of the observation group were (82.43 ± 5.63), (85.32 ± 5.47), (87.35 ± 4.27) and (84.42 ± 4.16) (71.53 ± 4.26), (74.36 ± 4.52), (75.55 ± 5.36) and (72.14 ± 4.53) in the control group, the difference was statistically significant (t = 9.7645,9.7687,10.8902,12.6279, P <0.05). Conclusions The combination of memantol and pramipexole in the treatment of Parkinson’s disease has remarkable clinical effect, which effectively improves the depressive symptom, improves the quality of life and clinical cure rate of patients, and is worthy of clinical promotion.